PressOctober 28, 2025 Delix reports positive Phase 1b data for non-hallucinogenic DLX-001 and FDA clearance of at-home Phase 2
PressOctober 23, 2025 Silo Pharma updates SPC-15 PTSD program and adds digital-asset treasury strategy
PressOctober 16, 2025 FDA grants Breakthrough Therapy designation to BPL-003 for treatment-resistant depression
PressSeptember 24, 2025 FDA approves NRx suitability petition for preservative-free ketamine strength
PressSeptember 23, 2025 atai and Beckley report positive Phase 2a two-dose BPL-003 data in treatment-resistant depression
PressSeptember 18, 2025 Colorado advisory board votes to recommend adding ibogaine to regulated healing centers
PressSeptember 18, 2025 atai awarded NIH grant of up to $11.4 million for non-hallucinogenic opioid use disorder program
PressSeptember 16, 2025 Reunion Neuroscience upsizes Series A to $133 million after positive trial data
